Savara (NASDAQ:SVRA) Research Coverage Started at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of Savara (NASDAQ:SVRA) in a research note released on Wednesday, MarketBeat Ratings reports. The firm issued an overweight rating and a $12.00 price objective on the stock.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. Citigroup restated a “market outperform” rating on shares of Savara in a research report on Wednesday. Royal Bank Of Canada set a $10.00 price objective on shares of Savara in a research note on Wednesday. Finally, Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.25.

Savara Stock Performance

Shares of SVRA stock opened at $4.92 on Wednesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13. Savara has a fifty-two week low of $3.35 and a fifty-two week high of $7.01. The stock has a 50 day moving average price of $5.32 and a two-hundred day moving average price of $5.41. The company has a market capitalization of $1.01 billion, a P/E ratio of -8.48 and a beta of 0.20.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Analysts expect that Savara will post -0.66 earnings per share for the current year.

Institutional Trading of Savara

Several large investors have recently added to or reduced their stakes in SVRA. Sequoia Financial Advisors LLC purchased a new position in Savara during the 2nd quarter valued at $69,000. WINTON GROUP Ltd bought a new position in Savara in the 2nd quarter worth $151,000. Arizona State Retirement System lifted its position in shares of Savara by 34.0% in the 2nd quarter. Arizona State Retirement System now owns 25,445 shares of the company’s stock worth $157,000 after purchasing an additional 6,456 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Savara in the 2nd quarter worth about $194,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Savara by 120.5% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 116,222 shares of the company’s stock valued at $716,000 after purchasing an additional 63,504 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.